Glycopyrronium bromide/Neostigmine metilsulfate

格隆溴铵新斯的明

Report date: 2025/07/07 20:00:09

Base Information

Drug NameGlycopyrronium bromide/Neostigmine metilsulfate
Drug Alias Name格隆溴铵/新斯的明Glycopyrronium bromide/Neostigmine methylsulfate格隆溴铵/甲硫酸新斯的明Neostigmine methylsulfate/GlycopyrrolateNeostigmine methylsulfate and glycopyrrolate injection +[8] 
ClassificationSmall molecules
Mechanisms of ActionMuscarinic acetylcholine receptor antagonistsAcetylcholinesterase inhibitorsMuscle relaxation antagonists
TargetsMuscarinic acetylcholine receptorAcetylcholinesterase
Therapy Area/IndicationsNeuromuscular Blockade
Global Approved IndicationsNeuromuscular Blockade
Approved Indications in ChinaN/A
Original Approved Country/TerritoryAustria
Original Approved Date2020/09/23
Country/TerritoryUnited StatesAustriaMainland China
CombinationsYes Glycopyrronium BromideNeostigmine methylsulfate
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSintetica Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesSintetica GmbhAzurity Pharmaceuticals IncJiangsu Huatai Chenguang Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsNeuromuscular Blockade
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipedia